Kaleido Biosciences, Inc.
https://kaleido.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kaleido Biosciences, Inc.
UK Biopharma Looks To Learn From Flagship Pioneering And Make ‘Bigger Leaps’
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
Newly Unveiled Ampersand's CEO On ‘Programmable’ Medicines And Flagship’s Winning Formula
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice